Inactivated Rotavirus Vaccine

This project aims to develop and scale up an inactivated rotavirus vaccine (IRV), CDC-9, to address the limitations of current oral rotavirus vaccines (ORVs) in low- and middle-income countries, where reduced efficacy is driven by factors such as malnutrition, enteric co-infections, and interference from maternal
antibodies. The IRV is produced using Vero cell cultivation and thermal inactivation, preserving antigen integrity and enhance safety. It is administered intramuscularly to elicit stronger and more consistent systemic immunity, thereby improving protection in infants for whom ORVs underperform. The proposed work includes optimizing upstream and downstream manufacturing processes, increasing production yield, and completing early-phase clinical trials to demonstrate safety and immunogenicity, with the ultimate goal of supporting global immunization efforts and reducing mortality from severe diarrheal disease in children.